ACADIA Pharmaceuticals Inc Q3 2021 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Gavin Scott - JPMorgan Chase & Co, Research Division - Analyst : This is Gavin on for Cory. We had a question actually on the DRP regulatory review. Karuna is expected to invest their drug candidate for DRP but are now planning to launch a Phase III next year in ADP specifically. Have you had any feedback from the agency about how they're broadly thinking about the DRP setting relative to the independent components, as this development would seem to increase it to help your case?

Question: Gavin Scott - JPMorgan Chase & Co, Research Division - Analyst : I just said that this development would seem to help your case.

Question: Gregory James Renza - RBC Capital Markets, Research Division - Analyst : Steve and team, congratulations on the quarter. Steve, just a follow-up on the regulatory update that's expected and as you proceed with engaging the FDA. I know you -- in the past year, you have characterized the stance as more of an agree to disagree position with respect to the totality of DRP versus the subgroups. And I'm just curious if you can comment quickly on how that's evolved, if that's changed as you're going into the subgroup meeting or the meeting on the subgroup with respect to starting with Alzheimer's disease. And just your level of enthusiasm that that's the right way to proceed with the DRP indication going forward.